Tumor Volume Combined With Number of Positive Lymph Node Stations Is a More Important Prognostic Factor Than TNM Stage for Survival of Non-Small-Cell Lung Cancer Patients Treated With (Chemo)radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 4, 2008, Pages 1039-1044

  Dehing Oberije, Cary ^a   De Ruysscher, Dirk ^a   van der Weide, Hiska ^a   Hochstenbag, Monique ^a   Bootsma, Gerben ^b   Geraedts, Wiel ^b   Pitz, Cordula ^c   Simons, Jean ^d   Teule, Jaap ^a   Rahmy, Ali ^b   Thimister, Paul ^b   Steck, Harald ^e   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c LAURENTIUS HOSPITAL   (Netherlands)

^d Department of Pulmonology   (Netherlands)

^e SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Nodal involvement; Non small cell lung cancer; Positron emission tomography; Prognostic factor; Staging; Tumor volume

Indexed keywords

CELLS; CHEMOTHERAPY; MEDICAL IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

LYMPH NODE STATIONS; NON-SMALL-CELL LUNG CANCER; PROGNOSTIC FACTOR; TUMOR VOLUME;

TUMORS;

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 39749138382     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.07.2323     Document Type: Article

References (37)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
2. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22 (2004) 330-353
3. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122 (2002) 1037-1057
4. Buccheri G., and Ferrigno D. Prognostic factors in lung cancer: Tables and comments. Eur Respir J 7 (1994) 1350-1364
5. Firat S., Byhardt R.W., and Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54 (2002) 357-364
6. Tammemagi C.M., Neslund-Dudas C., Simoff M., et al. Impact of comorbidity on lung cancer survival. Int J Cancer 103 (2003) 792-802
7. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev (2000) CD002139
8. Solan M.J., and Werner-Wasik M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 21 (2003) 64-73
9. Bradley J.D., Ieumwananonthachai N., Purdy J.A., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52 (2002) 49-57
10. Ball D., Smith J., Wirth A., et al. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 54 (2002) 1007-1013
11. Basaki K., Abe Y., Aoki M., et al. Prognostic factors for survival in Stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume. Int J Radiat Oncol Biol Phys 64 (2006) 449-454
12. Stinchcombe T.E., Morris D.E., Moore D.T., et al. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer 52 (2006) 67-74
13. Schrevens L., Lorent N., Dooms C., et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 9 (2004) 633-643
14. Kramer H., Post W.J., Pruim J., et al. The prognostic value of positron emission tomography in non-small cell lung cancer: Analysis of 266 cases. Lung Cancer 52 (2006) 213-217
15. Casali C., Stefani A., Natali P., et al. Prognostic factors in surgically resected N2 non-small cell lung cancer: The importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg 28 (2005) 33-38
16. Senan S., De Ruysscher D., Giraud P., et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
17. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
18. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy (1993), International Commission on Radiation Units and Measurements, Bethesda, MD
19. Fowler J.F., Tome W.A., Fenwick J.D., et al. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60 (2004) 1241-1256
20. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
21. Steyerberg E.W., Harrell Jr. F.E., Borsboom G.J., et al. Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54 (2001) 774-781
22. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 19 (1974) 716-723
23. Blanchon F., Grivaux M., Asselain B., et al. 4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index. Lancet Oncol 7 (2006) 829-836
24. Langendijk H., de Jong J., Wanders R., et al. The relevance of the revised version of the international lung cancer staging system for non-small-cell lung cancer treated with radiotherapy. Clin Lung Cancer 3 (2001) 33-36
25. Berghmans T., Lafitte J.J., Thiriaux J., et al. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer 45 (2004) 339-348
26. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48 (2000) 1475-1482
27. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63 (1997) 1441-1450
28. Andre F., Grunenwald D., Pignon J.P., et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
29. van Der Wel A., Nijsten S., Hochstenbag M., et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: A modeling study. Int J Radiat Oncol Biol Phys 61 (2005) 649-655
30. Buccheri G., and Ferrigno D. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 34 (2001) 433-440
31. Tammemagi C.M., Neslund-Dudas C., Simoff M., et al. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 57 (2004) 597-609
32. Belani C.P., Marts S., Schiller J., et al. Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 55 (2007) 15-23
33. Komaki R., Scott C.B., Byhardt R., et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four Radiation Therapy Oncology Group (RTOG) studies in inoperable non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 42 (1998) 263-267
34. Borst G.R., Belderbos J.S., Boellaard R., et al. Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41 (2005) 1533-1541
35. Davies A., Tan C., Paschalides C., et al. FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients. Lung Cancer 55 (2007) 75-78
36. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
37. van Baardwijk A., Bosmans G., Boersma L., et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 68 (2007) 771-778